Read more about the Vivally® System
Read more about the Vivally® System
Dive into our clinical studies to learn more about the Vivally® System and neuromodulation therapy.
Featured References
Goudelocke C, Sobol J, Poulos D, Enemchukwu E, Zaslau S, Dhir R. A Multicenter Study Evaluating the FREquency of Use and Efficacy of a Novel Closed-Loop Wearable Tibial Neuromodulation System for Overactive Bladder and Urgency Urinary Incontinence (FREEOAB). Urology. 2024 Jan;183:63-69. doi: 10.1016/j.urology.2023.10.007.
Goudelocke C, Elser-Poulos D, et al. A Personalized, Surgery-free Wearable Bladder Modulation and Digital Therapy System to Treat OAB Shows Comparable Results to More Invasive Treatments. Poster presented at: The American Urogynecologic Society (AUGS) and International Urogynecological Association (IUGA) Scientific Meeting; June 14-18, 2022; Austin, Texas.
Elser-Poulos D, Gerig N, et al. A Smart, Closed-Loop, Surgery-Free Wearable Bladder Modulation System With Objective Confirmation of Nerve Activation Used in the Home Is Easy to Use and Can Improve OAB Symptoms in 12 Weeks. Poster presented at: Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction; February 22-26, 2022; San Diego, California.
Elser D, Gerig N, et al. Emerging Nonsurgical, Wearable Neuromodulation System Shows Strong Patient Satisfaction, Likelihood to Use and Compliance in Clinical Study. Abstract presented at: International Continence Society (ICS) Meeting; October 14-17, 2021; Melbourne, Australia.
Gerig N, Cameron T, Arora S, Spear J, Lescozec L, Zhang M. Do we need more patient-friendly treatment options for overactive bladder (OAB)? Neurourol Urodyn. 2021 Aug;40(6):1433-1440. doi: 10.1002/nau.24731. Epub 2021 Jun 21.
Abedi A, Sayegh AS, Ha NT, La Riva A, Perez LC, Kohli P, Abedi A, Jen RP, Ginsberg DA, Kreydin EI. Health Care Economic Burden of Treatment and Rehabilitation for Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review. J Urol. 2022 Oct;208(4):773-783.
Kraus SR, Shiozawa A, Szabo SM, Qian C, Rogula B, Hairston J. Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States. Neurourol Urodyn. 2020 Nov;39(8):2206-2222.